Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action

scientific article published on 01 August 1983

Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action is …
instance of (P31):
scholarly articleQ13442814

External links are
P953full work available at URLhttp://cancerres.aacrjournals.org/cgi/content/abstract/43/8/3493
P698PubMed publication ID6190553

P2093author name stringR. L. Momparler
P. A. Jones
V. L. Wilson
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectchemotherapyQ974135
P304page(s)3493-3496
P577publication date1983-08-01
P1433published inCancer ResearchQ326097
P1476titleInhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action
P478volume43

Reverse relations

cites work (P2860)
Q24628329A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
Q54485278Cell cycle effects and cellular pharmacology of 5-AZA-2?-deoxycytidine
Q37479882Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
Q36466835Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia
Q35831786DNA Methylation Modulates Nociceptive Sensitization after Incision
Q30498513DNA methylation and differentiation
Q36920588Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance
Q43860783Effect of cytidine analogs on cell growth and differentiation on a human neuroblastoma line
Q52674783Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer.
Q37824255Epigenomics in cancer management
Q34768789Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies
Q38529787Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer
Q38825067Mechanistic insights into epigenetic modulation of ethanol consumption
Q43247519Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.
Q35164242Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Q33393266Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Q39102674Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected].
Q54527773Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression.
Q67535907Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin
Q37634505Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents
Q33431584The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Q41894605The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
Q37765469Therapy with azanucleosides for myelodysplastic syndromes
Q35939534Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

Search more.